Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.84
+0.01 (0.26%)
At close: Dec 29, 2023, 4:00 PM
3.77
-0.07 (-1.82%)
After-hours: Dec 29, 2023, 7:19 PM EST
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 stock analysts, the average 12-month stock price forecast for ABOS stock stock is $12.6, which predicts an increase of 228.13%. The lowest target is $8.00 and the highest is $15. On average, analysts rate ABOS stock stock as a strong buy.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ABOS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +108.33% | Dec 12, 2023 |
| Credit Suisse | Credit Suisse | Buy Reiterates $13 | Buy | Reiterates | $13 | +238.54% | Aug 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +290.63% | Aug 9, 2023 |
| B of A Securities | B of A Securities | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +264.58% | Jul 20, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $13 | Buy | Reiterates | $13 | +238.54% | Jul 17, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.07
from -1.06
EPS Next Year
-1.19
from -1.07
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | n/a | 27.9M |
| Avg | n/a | n/a | n/a | n/a | n/a | 13.5M |
| Low | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | - |
| Avg | - | - | - | - | - | - |
| Low | - | - | - | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -1.04 | -0.91 | -1.34 | -1.71 | -1.86 | -1.46 |
| Avg | -1.07 | -1.19 | -1.49 | -1.66 | -1.81 | -1.42 |
| Low | -1.07 | -1.35 | -1.67 | -1.60 | -1.73 | -1.36 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | - |
| Avg | - | - | - | - | - | - |
| Low | - | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.